On-Demand Sessions

Events » 27th Annual Conference » On-Demand Sessions

On-demand sessions will be recorded in advance and available for viewing through 30 November.

Plenary Sessions

Plenary: Cutting Edge Research Plenary

Sponsored by Pfizer


The Cutting Edge Research plenary session features some of the highest-ranked, innovative research from ISOQOL abstract submissions. In particular, these abstracts reflect research that truly “pushes the ISOQOL envelope” in providing new and different ways to look at quality of life.



Galina Velikova, MD PhD FRCP, Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds Cancer Centre, Leeds, United Kingdom

Phase III randomised controlled trial of eRAPID (electronic patient self-Reporting of Adverse-events: Patient Information and advice)—An eHealth intervention during chemotherapy

Professor Galina Velikova is an academic Medical Oncologist at the University of Leeds and Leeds Teaching Hospitals, UK with over 20 years’ track record of successful patient-centred research using electronic Patient-Reported Outcome Measures in daily practice and clinical trials. She led a National Institute for Health Research (NIHR) 5-year Programme Grant for applied research on patient self-reported symptoms and toxicity, using an online reporting system (QTool), uniquely integrated in electronic records, along re-designed care pathways for remote monitoring during cancer treatment to improve patient safety. Further research projects evaluate the use of the electronic system for remote monitoring and follow-up of cancer patients after treatment.

Professor Velikova has experience in leading collaborative research, both nationally and internationally such as Quality of Life sub-studies of international breast cancer trials (TACT2, SUPREMO). She is the past Chair of the British Psychosocial Oncology Society; past Chair of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group; and past President of the International Society for Quality of Life Research (ISOQOL). Professor Velikova is currently the Co-Chair of the National Cancer Research Institute (NCRI) Living with and Beyond Cancer Group and is also a member of the board of the EORTC.

Professor Velikova is a practising oncologist (Consultant in Medical Oncology) with clinical work focused on systemic treatment of breast cancer patients with early and advanced disease.


Antoine Regnault, PhD, Partner & Global Lead – Statistics Modus Outcomes, Lyon, France

Providing Meaningful Interpretation of a Performance Outcome Measure by Co-Calibration with a Patient-Reported Outcome: Illustration with Widely Used Multiple Sclerosis Measures

Antoine is a biostatistician with a strong interest in measurement science applied to patient-centered outcomes. As a consultant, he uses his combined skillset in psychometrics and statistics to support pharmaceutical companies with their analyses of patient-centered outcomes data from clinical trials and observational studies in a wide variety of disease areas (oncology, hematology, neurology and rare diseases, among others). He currently is a member of the Board of Directors of the International Society of Quality of Life (ISOQOL) and has been a member of international research initiatives such as SPIRIT-PRO and NeuroMET-2.


Sally Lewis, MRCGP, Aneurin Bevan University Health Board and Welsh Government, Cardiff, United Kingdom

Value Based Healthcare – a Welsh (UK) approach to delivering what matters to patients and clinicians

Sally has front-line experience of primary care at its most challenging having been senior partner and GP trainer in a practice in the Welsh valleys. She entered a career in medical management in 2011 and was appointed to Assistant Medical Director for value-based care in the Aneurin Bevan University Health Board in 2014.

Still practising as a GP, Sally is now National Clinical Lead for Value-based and Prudent Healthcare in Wales, and Honorary Professor at Swansea School of Medicine. Her current interests include the utilisation of value-based principles to allocate resource in publicly funded systems, patient outcome data and digital transformation


Tolulope “Tolu” Sajobi, PhD, University of Calgary, Calgary, Alberta, Canada

A Meta-analysis of Response Shift Effects in Patient-Reported Outcomes Studies

Dr. Sajobi is Associate Professor of Biostatistics in the Department of Community Health Sciences at the University of Calgary, Canada. He has a long standing interest in statistical methods for measurement and analysis patient-reported outcomes in clinical trials and observational studies. He is currently exploring novel latent variable models and machine learning algorithms for response shift detection in longitudinal patient-reported outcomes studies.




Todd DeWees, PhD

Plenary: “Hello, is it me you’re looking for?”: Measuring what matters to us.

Sponsored by EORTC


A plenary session focused on patient engagement and led by patient advocates. The goal of this plenary is to stimulate discussion regarding theory, methods and application of optimal patient and advocate involvement.



Allyson Berent, DVM DACVIM, Foundation for Angelman Syndrome Therapeutics and GeneTx Biotherapeutics, New York, New York, United States

Dr. Allyson Berent graduated from Cornell University College of Veterinary Medicine in 2002 and completed a residency in veterinary internal medicine at the University of Pennsylvania in 2005, followed by a fellowship in interventional radiology and endourology at the University of Pennsylvania and Thomas Jefferson University. Since 2009, she serves as the director of the Interventional Endoscopy Service at the Animal Medical Center in NYC. Dr. Berent is the CSO of the Foundation for Angelman Syndrome Therapeutics and the Chief Operating Officer for GeneTx Biotherapeutics, developing a novel antisense olignonucleotide for the treatment of Angelman syndrome, as rare neurogenetic disorder.


Kemi Doll, MD MSCR, University of Washington School of Medicine; Co-founder, Endometrial Cancer Action Network for African-Americans (ECANA), Seattle, Washington, United States

Dr. Kemi Doll is a gynecologic oncologist and Assistant Professor in the Department of OBGYN and an Adjunct Assistant Professor in the Department of Health Services in the School of Public Health. Her research centers on examining Black-White racial inequity in the care of benign and malignant gynecologic disease in the US. Her research has been funded by the NIH, the Robert Wood Johnson Foundation, and the Patient Centered Outcomes Research Institute (PCORI). She is the co-founder of ECANA, the Endometrial Cancer Action Network for African-Americans (ecanawomen.org) a community-research partnership formed to improve survival among Black women with endometrial cancer.




Elizabeth Unni, PhD MBA Bpharm

Plenary: “It’s not about the money, money, money”: Or is it? The future of value-based healthcare and outcomes-based pricing.


Innovations in healthcare technology are putting increasing pressure on constrained healthcare budgets, and this has led to an emergence of outcomes-based pricing models. The goal of this plenary is to discuss how clinical outcome assessment data are being incorporated into these access systems as well as the benefits and limitations of this model.



Lotte Steuten, PhD, Office of Health Economics, London, United Kingdom

Lotte Steuten, PhD, is Vice-President and Head of Consulting at the Office of Health Economics and Honorary Visiting Professor at City, University of London, UK. Lotte specialises in providing research-based and client-focused analysis and expertise to informing decisions regarding healthcare policy, pricing and regulation of pharmaceuticals, and health technology assessment (HTA). She effectively collaborates with technology assessors, payers and policy makers, (academic) researchers, clinical and patient representatives, pharmaceutical industry and capital investors. Lotte has contributed to the health economics and outcomes research for >15 years in various academic roles and executive functions in the UK, US and the Netherlands.


Paula Williamson, PhD FRSS FMedSci, COMET Initiative Management Group, University of Liverpool, Liverpool, United Kingdom

Paula Williamson is Professor of Biostatistics at the University of Liverpool, and was Head of the Department of Biostatistics from 2002 until 2018. Her research has focussed on clinical trials, meta-analysis, and health outcome selection. Paula leads the MRC/NIHR Trials Methodology Research Partnership. She is an NIHR Senior Investigator, a Fellow of the Academy of Medical Sciences, and gave the Bradford Hill Lecture in 2017. Paula co-founded the (Core Outcome Measures in Effectiveness Trials) Initiative in 2010, to improve the quality and relevance of health research to decision makers including patients, health professionals, regulators and policymakers.


Stefan Larsson, MD PhD, The Boston Consulting Group, Stockholm, Sweden

Stefan Larsson joined the Boston Consulting Group in 1996 and is a Senior Partner and a BHI Fellow. Stefan has lead strategy assignments and major transformational programs across all sectors of the healthcare industry: Academic medical centers; leading international providers; Biopharma; Biotech and MedTech – from R&D through commercial. He is a cofounder and board member of ICHOM. Stefan has been BCG‘s global sector leader for Healthcare Payers and Providers and later the Healthcare Systems sector. Stefan is an MD, PhD and Associate professor at the Karolinska Institute (KI). Stefan trained at Harvard MS, MRC-HGU, Edinburgh and EMBL Heidelberg.




Patricia Corey-Lisle, PhD MSN

Plenary: “Video killed the radio star”: How technology is changing the way we collect, analyze and interpret patient-relevant data.


The goal of this plenary session is to hear how technology is impacting our work. We will hear from innovators working both inside and outside our field as they paint a picture for the future of outcomes measurement and quality of life research.



Marie Deserno, PhD, Max Planck Institute for Human Development, Berlin, Germany

Dr. Marie Deserno is a postdoctoral research fellow at the Formal Methods group of the Max Planck Institute for Human Development in Berlin, Germany. Supported by a NWO Rubicon fellowship her research deals with models of change in developmental psychology and quality of life research in the autistic community. Her work is strongly rooted in the network approach to psychology developed at the Psychosystems group (University of Amsterdam) and sits at the intersection of developmental psychology and psychological methods.


Katarzyna Wac, PhD, University of Geneva, Quality of Life Technologies Lab, Geneva, Switzerland

Katarzyna Wac is a Professor of Health Informatics at the Department of Computer Science, University of Copenhagen, Denmark, and at the University of Geneva, Switzerland, affiliated with Stanford University since 2013. Dr. Wac leads Quality of Life (QoL) Technologies lab researching how mobile and emerging sensor-based technologies can be leveraged for an accurate, longitudinal personalized assessment of the individual’s behavior and QoL, as they unfold naturally over time and in context, and the improvement of the latter. More info at katarzynawac.org.


Kim Oostrom, PhD, University of Amsterdam Medical Center, Amsterdam, Netherlands







Chris Sidey-Gibbons, PhD


Concurrent symposium sessions showcase the research and science of the ISOQOL community. Symposium sessions are selected following peer review of submitted abstracts. Access to symposium sessions is included in conference registration.

Symposium 1: Extending the QALY (E-QALY): developing a new international preference-based outcome measure for health and quality of life


John Brazier, PhD, School of Health and Related Research, The University of Sheffield, Sheffield, United Kingdom


Madeleine King, Cancer Australia Chair in Cancer Quality of Life, School of Psychology, University of Sydney, Sydney, New South Wales, Australia

Individual Presentations:

EXTENDING THE QALY (E-QALY): Developing a new generic preference-based measure for use with patients, carers and those needing care – an overview

John Brazier, PhD, School of Health and Related Research, The University of Sheffield, Sheffield, United Kingdom

E-QALY: Identifying dimensions and items for a generic preference-based measure

Clara Mukuria, University of Sheffield, Sheffield, United Kingdom

E-QALY: Psychometric testing and selecting the items for a new generic preference-based measure

Ole Marten, MSc, School of Public Health, Department of Health Economics and Health Care Management, Bielefeld University, Bielefeld, Germany

E-QALY: Face validity testing the items for a new generic preference-based measure 

Zhihao Yang, PhD, Jinan University, Guangzhou, China

E-QALY: Valuing the items for a new generic preference-based measure using time trade-off and discrete choice experiments

Donna Rowen, PhD, University of Sheffield, Sheffield, United Kingdom

Symposium 2: Do you know what I mean? Interpreting PRO/HRQOL scores at group and individual level.


Corneel Coens, EORTC HQ, Brussels, Belgium


Galina Velikova, PhD MD, Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds Cancer Centre, Leeds, United Kingdom

Madeleine King, PhD, University of Sydney, Sydney, Australia; Submitted on behalf of EORTC Quality of Life Group

Individual Presentations:

Interpretation of patient reported outcome data at group-level versus individual-level; can we use the same clinical meaningful thresholds for both scenarios?

Jammbe Musoro, PhD, EORTC HQ, Brussels, Belgium

Development and use of thresholds for clinical importance to facilitate interpretation of scores from patient-reported outcome measures

Johannes Giesinger, PhD, Medical University of Innsbruck, Innsbruck, Austria

Norm data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons from the European general population, Canada, and the USA.

Sandra Nolte, PhD, ICON plc, Berlin, Germany

Symposium 3: Using an implementation science approach to implement and evaluate Patient Reported Outcome Measures (PROM/PREM) initiatives in routine care settings


Angela Stover, PhD, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States 


Maria Santana, PhD, University of Calgary, Alberta, Canada

Individual Presentations:

One vehicle, too many wheels: towards consistent use of theory for guiding the implementation of PROMs/PREMs in routine clinical practice

Caroline Potter, PhD, University of Oxford, Oxford, United Kingdom

Implementation of PROMs in routine clinical care within an integrated pain network

Sara Ahmed, PhD, McGill University, Montreal, Quebec, Canada

Using the Integrated framework Promoting Action Research in Health Services (iPARIHS) Framework to study implementation of PROMs into oncology care

Natasha Roberts, PhD, Queensland University of Technology, Kelvin Grove, Australia

Using Implementation Science to Inform Integration of Electronic Patient-Reported Experience Measures (ePREMs) into Healthcare Quality Improvement

Kimberly Manalili, PhD Candidate, University of Calgary, Calgary, Alberta, Canada

Implementation of the KLIK PROM portal using the Consolidated Framework for Implementation Research (CFIR) retrospectively

Hedy van Oers, PhD, Emma Children’s Hospital Amsterdam UMC, Amsterdam, Netherlands

Implementation science metrics to evaluate patient-reported outcome measure (PROM) implementation initiatives in routine care settings

Angela Stover, PhD, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Symposium 4: Optimizing Power and Precision in Rare Disease PRO Endpoints

Sponsored by Pharmerit


Pronabesh Dasmahapatra, MD MPH, Head, Heath Economics and Value Assessment Strategy, Rare Disease and Rare Blood Disorder, Cambridge, Massachusetts, United States

Individual Presentations:

Most Bothersome Symptom in Rare Disease: A Look at Endpoint Precision and Validity

R. J. Wirth, PhD, Vector Psychometric Group, LLC, Chapel Hill, North Carolina, United States

Hypothesis Tests to Evaluate Treatment Efficacy that Optimize Power and Precision in Rare Disease Settings

Charles Iaconangelo, PhD, Pharmerit – an OPEN Health Company, Brooklyn, New York, United States

A New Method for Testing Significance of eCDF Separation for Meaningful Change in Rare Diseases

Daniel Serrano, PhD, Pharmerit – an OPEN Health Company, Bethesda, Maryland, United States

Symposium 5: Integrating Adverse Event Data and Patient-Reported Outcomes to Better Understand Cancer Treatment Tolerability: The US National Cancer Institute-Funded Tolerability Consortium


Gita Thanarajasingam, MD, Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States

Individual Presentations:

Analytic and Interpretation Approaches for PRO-CTCAE, CTCAE, and Other Clinical Data to Characterize Drug Tolerability

Amylou Dueck, PhD, Mayo Clinic, Scottsdale, Arizona, United States

Measuring the Tolerability of Cancer Therapy: Incorporating Host Factors as Moderators of Toxicity and Outcomes

Patricia Ganz, MD, Department of Health Policy and Management, UCLA Fielding School of Public Health, Los Angeles, California, United States

Relationships between aging-related conditions and treatment tolerability in older adults with advanced cancer

Eva Culakova, PhD, University of Rochester, Rochester, New York, United States

Analysis of ECOG-ACRIN Clinical Trials to Advance Longitudinal Assessment of Cancer Treatment Tolerability

John Devin Peipert, PhD, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

Symposium 6: From single site to scale: What does it take to implement PROs across health systems?


Danielle C. Lavallee, PharmD PhD, University of Washington, Seattle, Washington, United States.

Individual Presentations:

Recommendations for governing PRO use across health systems

Danielle C. Lavallee, PharmD PhD, University of Washington, Seattle, Washington, United States

Governing PROs across health systems: Case study at University of Utah

Rachel Hess, MD MS, University of Utah, Salt Lake City, Utah, United States

Recommendations for integrating PROs into clinical care delivery

Elizabeth Austin, University of Washington, Seattle, Washington, United States

Integrating PROs into care delivery: Case study at University of Pittsburgh Medical Center

Janel Hanmer, MD PhD, University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Symposium 7: Application and value of qualitative in-trial or ‘exit’ interviews to generate supplementary evidence regarding patients’ trial, treatment and disease experiences: examples from multiple disease areas


Sophi Tatlock, Adelphi Values Ltd, Bollington, United Kingdom

Individual Presentations:

Using qualitative exit interviews to explore the disease experience and evaluate Performance-Reported Outcomes (PerfOs) with patients who experience muscle weakness

Maggie Tabberer, MSc, GlaxoSmithKline, London, United Kingdom

Qualitative exit interviews with study clinical investigators to explore trial and treatment experience and feasibility of use in general clinical practice

Nicola Williamson, Adelphi Values Ltd, Bollington, United Kingdom

Patient perspectives on the benefit of a novel therapy for a rare disease: Using qualitative exit interviews to inform post-launch value messaging and to support shared treatment decision-making

Parth Vashi, PharmD, Bayer Pharmaceuticals, Whippany, New Jersey, United States

Use of qualitative exit interviews to explore individual experiences of treatment and meaningful change in two clinical trials for autism spectrum disorder.

Elizabeth Gibbons, MSc, Clinical Outcomes Solutions, Folkestone, United Kingdom

Symposium 8: Making sense of sensors: Selecting, incorporating, and analyzing fit-for-purpose technologies for continuous data capture in clinical trials


Philip Griffiths, PhD, Adelphi Values, Bollington, United Kingdom


Michelle Campbell, U.S. Food and Drug Administration, Silver Spring, Maryland, United States

Individual Presentations:

How can transdisciplinary collaboration help us ensure that the digital medicine tools we are being asked to place our trust in are indeed trustworthy?

Jennifer Goldsack, MChem MA MBA, Digital Medicine Society (DiMe), Boston, Massachusetts, United States

Industry Considerations for the use of Technologies for Continuous Data Capture

Jiat Ling Poon, PhD, Eli Lilly and Company, Indianapolis, Indiana, United States

Technologies for continuous data capture in clinical trials – the logistics of makings it happen

Paul O’Donohoe, Medidata, London, United Kingdom

Technologies for continuous data capture: Discussing dilemmas with data and considering potential analysis approaches

Carrie Houts, Vector Psychometric Group, Tempe, Arizona, United States

Symposium 9: Using the estimand framework to align study design and analysis with patient-reported outcome objectives: the times they are a-changin’


Bellinda King-Kallimanis, PhD, U.S. Food and Drug Administration, Silver Spring, Maryland, United States
Madeline Pe, PhD, EORTC Quality of Life Department, Brussels, Belgium

Individual Presentations:

An HTA perspective on the treatment policy estimand if the endpoint is repeatedly measured over time

Christoph Schürmann, Dr., IQWiG – Institute for Quality and Efficiency in Health Care, Cologne, Germany

Why & how to use time-to-event endpoints for COAs & how can the estimand framework help?

Rachael Lawrance, Adelphi Values Ltd, Bollington, United Kingdom

Applying the Estimand Framework to Describe Patient Experience While on Treatment: A Case Study

Mallorie Fiero, PhD, U.S. Food and Drug Administration, Silver Spring, Maryland, United States

Symposium 10: The future of electronic patient-reported outcome measurement for children and adolescents: the use of computer adapted testing


John Chaplin, PhD, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

Individual Presentations:

The Kids-CAT: a computer adaptive tool to measure quality of life in children and adolescents. Development, validation and implementation in clinical settings and population health reporting

Christiane Otto, PhD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

From translation to implementation: the challenge of PROMIS® CATs in daily pediatric practice.

Michiel Luijten, Emma Children’s Hospital, Amsterdam UMC, Amsterdam, Netherlands

Comparison of PROMIS Computerized Adaptive Testing-Administered Item Banks versus Fixed Short Forms in Juvenile Myositis

Kaveh Ardalan, MD MS, Duke University School of Medicine, Durham, North Carolina, United States

Using CATs to measure symptom burden reported by children with brain tumors

Jin-Shei Lai, Northwestern University, Chicago, Illinois, United States

Application of the Kids-CAT in the clinical setting: Predictors of health-related quality of life in children and adolescents with chronic diseases

Kathrin Fischer, Charité Universitatsmedizin Berlin, Berlin, Germany

SIG Symposia

Three concurrent symposia hosted by ISOQOL Special Interest Groups (SIGs) will be held. These symposia provide educational content related to the special interest and expertise of the groups hosting the session. SIGs had the opportunity to submit a proposal and the presenting groups rotate annually to ensure parity and differentiation of content.

This year, the following SIGs and symposia have been selected:

Industry SIG: Item Bank for your Buck: Successfully Harnessing the Power of Item Banks and Libraries to Assess Clinical Benefit from the Patient Perspective


Linda Nelsen, MHS, GlaxoSmithKline, United States


David Cella, PhD, Northwestern University, United States
Heather Gelhorn, PhD, Evidera, Bethesda, United States
Antoine Regnault, PhD, Modus Outcomes, France
Jill Bell, PhD, Takeda Oncology, United States


Elektra Papadopoulos, MD MPH, U.S. Food and Drug Administration, United States

Items banks and libraries such as PROMIS, PRO-CTCAE and EORTC Item Library support measurement of PRO concepts across therapeutic areas. Creating custom PRO measures, or short-forms, from item banks / libraries may enhance measurement precision and validity, and reduce resources required for PRO development. However, development of short forms optimized for use in specific target populations from these measurement systems requires a robust research plan, with clarity of concepts, rigorous qualitative research, and sophisticated psychometric methods.

This symposium will provide an overview of item banks and libraries, with examples of the application of these measurement systems for specific populations, highlighting benefits and challenges to their use.

Presentations will consider item selection approaches supporting appropriate content coverage and ensuring an understanding of measurement properties of these custom measures.  An interactive panel will discuss the value of item banks to patients, clinicians, and industry.

Mixed Methods SIG: The Application of Mixed Methods to Measure Health Outcomes in Clinical Trials, Clinical Practice, and Health Policy


Motolani Ogunsanya, BPharm MS PhD, University of Oklahoma Health Sciences Center, United States
Carla Dias Barbosa, MSc, Evidera, United Kingdom


Sophie Cleanthous, PhD, Modus Outcomes, United Kingdom
Mona Martin, PhD, Evidera, United States
Motolani Ogunsanya, BPharm MS PhD, University of Oklahoma Health Sciences Center, United States
Carla Dias Barbosa, MSc, Evidera, United Kingdom
Skye Barbic, PhD, University of British Columbia, Canada

Recent advances in mixed methods research (MMR) provide an opportunity to better understand patient experience with disease and/or treatment and impact on their quality of life (QOL) by integrating qualitative and quantitative methods in research design and using patient-reported outcome measures (PROMs) developed through robust patient engagement and advances in metrology.

This symposium will provide an overview of MMR in the context of health outcome research and highlight multiple international examples about the application of these methods in clinical trial research for evaluation of treatment benefit, PROM development, and testing and implementation of PROMs in clinical practice and policy. This symposium uses a graded learning approach by first introducing MMR in QoL research to the audience (presentation #1), use of MMR in PROM development (presentation #2), PROM testing and validation (presentation #3), treatment risk-benefit assessment in clinical trials (presentation #4) and PROM implementation in policy and system transformation (presentation #5).

Psychometrics and Response Shift SIGs: How to Assess and Interpret Measurement Properties and Change Over Time using Longitudinal Item Response Theory (LIRT)


Henrik Rode Eshoj, PhD, Odense University Hospital, Denmark


Frances M. Yang, PhD, University of Kansas Medical Center, United States
Andrew Trigg, MSc, Adelphi Values, United Kingdom
Philip Griffiths, PhD, Adelphi Values, United Kingdom
Jakob Bjorner, MD PhD, Optum Patient Insights, United States
Berend Terluin, MD PhD, Amsterdam University Medical Center, the Netherlands
Myriam Blanchin, PhD, University of Nantes, France


Carrie R. Houts, Vector Psychometric Group, United States

Item Response Theory (IRT) is normally used at a single timepoint. However, when longitudinal data is available other advantageous applications of IRT exist. In this context, IRT can be used to evaluate change, derive meaningful change thresholds and understand response shift. Additionally, longitudinal data may help support IRT models for instrument validation in small samples.

This symposium presents the “what, when, and how” of Longitudinal IRT (LIRT). Attendees will be introduced to the concepts of IRT and how to apply this in a longitudinal dataset to explore a tool’s measurement properties. We will build on this by showing examples of using LIRT to assess and interpret change and investigate and adjust for response shift. Content will be discussed by an experienced psychometrician, ensuring this complex topic will be delivered in a practical and accessible way.  Example code will be provided to help attendees apply LIRT to their own research.

Oral Sessions

Oral sessions are composed of 5-6 peer-reviewed abstracts clustered around one common theme. Recordings of individual 10 minute presentations will be available for viewing anytime during the virtual conference.

Oral Brief Sessions

Oral Brief sessions are composed of 10 abstracts in the same primary application category. Recordings of the individual 5 minute presentations will be available for viewing anytime during the virtual conference.

Poster Sessions

Poster sessions feature peer-reviewed abstracts in thematic groupings. Using the provided cloud-based software, all presenters will create a virtual poster that include text, images, links and audio clips to explain their research.

Awards and Member Business Meeting 

The Awards and Member Business Meeting includes presentation of annual awards, leadership transition, and official ISOQOL business. Since membership dues are included in the conference registration, all Annual Conference attendees are members and and encouraged to attend this session.

Tricks of the Trade Presentation

Organized by the New Investigator SIG

Karon Cook, PhD and Ida Korfage, PhD

How to Become Leaders in ISOQOL

Becoming a leader in a professional organization is a terrific opportunity for junior investigators. However, many of us wonder about the best ways to become leaders. This Tricks of the Trade session will allow attendees to identify available positions in ISOQOL and recognize clear barriers and facilitators to obtaining these leadership positions. Please join two internationally-recognized ISOQOL leaders as they share their personal experiences in leadership positions in ISOQOL, offer tips and suggestions on getting involved, and answer YOUR burning questions about leadership opportunities. Lessons learned from this session can be immediately put into practice during the annual conference!

Our Sponsors

The International Society for Quality of Life Research (ISOQOL) is a global community of researchers, clinicians, health care professionals, industry professionals, consultants, and patient research partners advancing health related quality of life research (HRQL).

Together, we are creating a future in which patient perspective is integral to health research, care and policy.